(tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Skip to content

Long-term Data
for Second Line+

MONJUVI is an outpatient targeted immunotherapy
for adult patients with NTE DLBCL in 2L1*

The 5-year analysis data from L-MIND have not been submitted to or reviewed by the FDA, and potential inclusion of these data in the final FDA-approved labeling has yet to be determined.

*MONJUVI is a CD19-directed cytolytic monoclonal antibody.1

Skip to NCCN Banner

Patient profiles

Review cases of candidates for
treatment with MONJUVI

View Profiles

Efficacy data

Discover more about the
clinical study results

Explore Efficacy

Expert perspectives

Find out what other hematology
specialists are saying

Play Expert Video